on Symrise AG (ETR:SY1)
Symrise AG Announces Divestment of Terpenes Business and Impairments
Symrise AG has revealed plans to divest its terpenes business, currently in advanced talks with potential buyers. This strategic move involves a structured bidding process, leading to a notable non-cash impairment charge of approximately EUR 145 million in Q4 of 2025. This decision impacts the company's EBIT negatively.
Additionally, Symrise AG faces a non-cash impairment related to its investment in Swedencare AB. Preliminary calculations indicate a charge of EUR 150 million for Q4 of 2025. This adjustment results in a material deviation from 2025 financial expectations, affecting EBITDA adversely.
These impairments do not influence Symrise AG's liquidity or daily operations and will be addressed in the company's earnings report.
R. E.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Symrise AG news